These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 8382322

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. IPD-1151T: a prototype drug for IgE antibody synthesis modulation.
    Koda A, Yanagihara Y, Matsuura N.
    Agents Actions Suppl; 1991; 34():369-78. PubMed ID: 1665310
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intravesical suplatast tosilate (IPD-1151T) inhibits experimental bladder inflammation.
    Boucher W, Kempuraj D, Cao J, Papaliodis D, Theoharides TC.
    J Urol; 2007 Mar; 177(3):1186-90. PubMed ID: 17296442
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Effects of suplatast tosilate (IPD-1151T) on antibody formations in mice].
    Matsuura N, Mori H, Nagai H, Koda A.
    Nihon Yakurigaku Zasshi; 1992 Dec; 100(6):485-93. PubMed ID: 1336470
    [Abstract] [Full Text] [Related]

  • 8. Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo.
    Kurokawa M, Kawazu K, Asano K, Fumio K, Mita A, Adachi M.
    Mediators Inflamm; 2001 Dec; 10(6):333-7. PubMed ID: 11817674
    [Abstract] [Full Text] [Related]

  • 9. Suppressive effects of IPD-1151T (suplatast-tosilate) on induction of mast cells from normal mouse splenocytes.
    Konno S, Adachi M, Asano K, Gonogami Y, Ikeda K, Okamoto K, Takahashi T.
    Eur J Pharmacol; 1994 Jun 23; 259(1):15-20. PubMed ID: 7957588
    [Abstract] [Full Text] [Related]

  • 10. Effect of IPD-1151T (Suplatast Tosilate) on airway hyperresponsiveness in mice.
    Konno S, Asano K, Gonokami Y, Kurokawa M, Kawazu K, Adachi M.
    Arerugi; 1995 May 23; 44(5):556-61. PubMed ID: 7619009
    [Abstract] [Full Text] [Related]

  • 11. [Inhibitory effect of IPD-1151T (suplatast tosilate) on mast cell induction from normal mouse spleen cells].
    Kouno S, Adachi M, Asano K, Okamoto K, Takahashi T.
    Arerugi; 1992 Oct 23; 41(10):1488-91. PubMed ID: 1336362
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells.
    Hsu LW, Yang CH, Goto S, Nakano T, Lai CY, Lin YC, Kao YH, Chen SH, Cheng YF, Jawan B, Chiu KW, Tsao FK, Chen CL.
    Transpl Immunol; 2007 Nov 23; 18(2):108-14. PubMed ID: 18005853
    [Abstract] [Full Text] [Related]

  • 15. IPD-1151T (suplatast tosilate) inhibits interleukin (IL)-13 release but not IL-4 release from basophils.
    Shichijo M, Shimizu Y, Hiramatsu K, Togawa M, Inagaki N, Takagi K, Nagai H.
    Jpn J Pharmacol; 1999 Apr 23; 79(4):501-4. PubMed ID: 10361893
    [Abstract] [Full Text] [Related]

  • 16. Down-regulation of Th2 cell-mediated murine peritoneal eosinophilia by antiallergic agents.
    Yamaya H, Basaki Y, Togawa M, Kojima M, Kiniwa M, Matsuura N.
    Life Sci; 1995 Apr 23; 56(19):1647-54. PubMed ID: 7723593
    [Abstract] [Full Text] [Related]

  • 17. [Reproductive and developmental toxicity study of suplatast tosilate (IPD-1151T) (1)--Fertility study in rats by oral administration].
    Aso S, Sueta S, Kajiwara Y, Morita S, Horiwaki S, Yamakita O.
    J Toxicol Sci; 1992 May 23; 17 Suppl 2():141-54. PubMed ID: 1321258
    [Abstract] [Full Text] [Related]

  • 18. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T.
    Ueda T, Tamaki M, Ogawa O, Yamauchi T, Yoshimura N.
    J Urol; 2000 Dec 23; 164(6):1917-20. PubMed ID: 11061880
    [Abstract] [Full Text] [Related]

  • 19. [Mutagenicity tests of suplatast tosilate (IPD-1151T)].
    Ohuchida A, Furukawa A, Sato S, Maeda Y, Kashihara A, Mizumoto T, Yoshida R.
    J Toxicol Sci; 1992 May 23; 17 Suppl 2():207-20. PubMed ID: 1321262
    [Abstract] [Full Text] [Related]

  • 20. CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate.
    Woerly G, Decot V, Loiseau S, Loyens M, Chihara J, Ono N, Capron M.
    Clin Exp Allergy; 2004 Sep 23; 34(9):1379-87. PubMed ID: 15347370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.